GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » ROE % Adjusted to Book Value

GILD (Gilead Sciences) ROE % Adjusted to Book Value : 6.33% (As of Dec. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Gilead Sciences ROE % Adjusted to Book Value?

Gilead Sciences's ROE % for the quarter that ended in Dec. 2024 was 37.73%. Gilead Sciences's PB Ratio for the quarter that ended in Dec. 2024 was 5.96. Gilead Sciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 6.33%.

Gilead Sciences ROE % Adjusted to Book Value Historical Data

The historical data trend for Gilead Sciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences ROE % Adjusted to Book Value Chart

Gilead Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 7.34 4.31 5.82 0.38

Gilead Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.73 -15.86 7.70 4.83 6.33

Competitive Comparison of Gilead Sciences's ROE % Adjusted to Book Value

For the Drug Manufacturers - General subindustry, Gilead Sciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's ROE % Adjusted to Book Value falls into.


Gilead Sciences ROE % Adjusted to Book Value Calculation

Gilead Sciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=2.28% / 5.96
=0.38%

Gilead Sciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=37.73% / 5.96
=6.33%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
PFE BMY AMGN MRK BIIB OGN AMRN SCLX MIRA ABBV LLY OCSE:NOVO B JNJ XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN TSE:4519 LSE:GSK TSE:4568
Traded in Other Exchanges
GILD:Peru GILD:Mexico 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD:Chile GILD34:Brazil GILD:Austria GILD:Argentina
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Website
https://www.gilead.com
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Executives
Andrew D Dickinson officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey officer: Chief Medical Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Jeffrey Bluestone director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Johanna Mercier officer: Chief Commercial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson officer: SVP, Controllership 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong officer: SVP, Controller & CAO 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman officer: EVP, Corporate Affairs & GC 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Anthony Welters director
Javier Rodriguez director 601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan director 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson director C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711